News

Eli Lilly (LLY) stock is back in focus after the FDA granted Breakthrough Therapy designation to its investigational drug olomorasib for KRAS G12C-mutant advanced pancreatic cancer, highlighting an expanding oncology effort. See our latest analysis for Eli Lilly. Eli Lilly’s share price has eased recently, with a 7 day share price return down 8.60% and a 30 day share price return down 8.09%. This is even though the 1 year total shareholder return sits at 46.69% and the 5 year total...

The Dow and S&P 500 hit new highs while the Nasdaq powered higher again. SpaceX, AMD and Arista led earnings movers late.

The healthcare giant showered its owners with cash, yet the stock fell behind. Here is the accounting of what investors actually got and what the trade-off cost them.

U.S.-traded shares of Novo Nordisk are down more than 6% due to a sales shortfall for its new Wegovy weight-loss pill and a disappointing study outcome for a next-generation weight-loss drug. Overall, the company sees the potential for a full-year sales decline of up to 6%, better than its previous view that sales could drop up to 12%. Novo also disclosed that its experimental drug CagriSema failed to show comparable blood-sugar reduction to Eli Lilly’s tirzepatide in a new study of people with Type 2 diabetes.

The Danish drugmaker continues to rely on the success of semaglutide, branded as Wegovy for weight loss and Ozempic for diabetes.

Lilly plans to file for FDA approval in the first quarter of next year

Novo Nordisk stock plummeted Tuesday after the obesity kingpin unexpectedly released its second-quarter earnings a day early.

Baron Capital, an investment management company, released its Q2 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 Health Care Index and the 15.44% gain for the Russell 3000 Index. Since inception, […]

Pfizer (PFE) delivered earnings and revenue surprises of +13.24% and +4.04%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Even if a megamerger fails to materialize, investors stand to benefit from a wave of M&A activity in the biopharma sector.

Eli Lilly's key catalyst for 2027 could positively affect price action sooner than you think.

Eli Lilly is scheduled to report earnings Wednesday morning, with traders expecting the drugmaker’s stock could potentially approach last month’s highs following the results.

Pfizer beats earnings forecasts for the second quarter, while BioNTech’s results miss expectations due to weak Covid vaccine demand.

(Bloomberg) -- Wall Street’s appetite for weight-loss drug stocks over the past four years has powered Eli Lilly & Co. to consistently trade above $1,000 per share. Now, some see the pharma giant’s stock as primed for a split.Most Read from BloombergBeer Dynasty Families Sell €731 Million Stake in AB InBevApple’s New CEO Taps Retired Hardware Executive for Management TeamTaco Bell Met With Michigan on Parasite Weeks Before RecallMamdani Dismisses Business Leaders Advising NYC’s Mayor’s FundS&P 5

Lilly’s recent deal to acquire AtaiBeckley gave the field a boost, but other biotechs still need to prove their clinical and commercial potential.

Today Earnings (a.m.): Merck, Pfizer, McDonald's, Caterpillar, Spotify, Apollo, TPG, Marathon Petroleum, Archer-Daniels-Midland, DuPont, Kimberly-Clark Earnings (p.m.): SpaceX, Advanced Micro Devices, ...

Even if a megamerger fails to materialize, investors stand to benefit from a wave of M&A activity in the biopharma sector.

Amplia Therapeutics Ltd (ASX:ATX, OTCQB:INNMF) has signed a clinical collaboration agreement with Eli Lilly and Company to evaluate its lead drug narmafotinib alongside Lilly’s next-generation KRAS G12C inhibitor olomorasib in patients with advanced non-small cell lung cancer (NSCLC). The...

Inspire Medical Systems (NYSE:INSP) reported second-quarter revenue of $200.6 million, down 7.6% from a year earlier, as coding and reimbursement disruptions continued to affect procedure volumes. The company said results exceeded its internal expectations for profitability and cash flow, prompting

The pharmaceutical giant sent shareholders a fortune in cash, yet the stock itself fell far behind the market. Here is the honest accounting of what owners actually got.

The FDA granted Breakthrough Therapy designation to Eli Lilly's olomorasib as a monotherapy for KRAS G12C-mutant advanced pancreatic cancer. This is the second Breakthrough Therapy designation for olomorasib, which targets a patient group with limited treatment options. Ratio Therapeutics raised US$70 million in a Series C round that included participation from Eli Lilly. Eli Lilly, traded as NYSE:LLY, has long been known for its focus on oncology, diabetes and immunology. The latest...

SKYRIZI supplies close to a third of guided company revenue, which puts an unusual amount of AbbVie's future behind one patent estate.

(Updates with market moves at the end of the day, and other changes, if any.) The Dow Jones Indus

The healthcare stock is up over 300% in five years and has a market cap of around $1 trillion.

Early data could widen Lilly's growth story beyond incretins

(Updates with latest market prices and developments.) US stocks climbed intraday as oil prices fe

Amgen, Pfizer, Eli Lilly, Merck and Novo Nordisk are set to report Q2 results this week after a strong start for pharma earnings. Which names could beat forecasts?

A Mizuho healthcare analyst says merging two of pharma's biggest names could unlock a fortune, but the math only works if one brutal condition is met.

As stocks like Eli Lilly, Twilio, Hinge Health and more move ahead of earnings report, pay attention to these chart lines.

The FTSE 100 index closed down 10.35 points, 0.1%, at 10,857.70.